Biosidus rozširuje výrobnú kapacitu biologických liečiv a možnosti globálnych dodávok agalsidázy beta

agalsidase betaPositive

AI Analysis

Summary

Biosidus, an Argentine biotechnology company, announces that its new bioreactor facility is now operational, expanding manufacturing capacity and global supply capabilities for agalsidase beta biosimilar.

Importance:3/10

Sentiment:

0.60

capacity expansionbiosimilarmanufacturingagalsidase beta

Read the original article

Published by PR Newswire Biotech on August 27, 2026 10:34 AM

Read Original